Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The presynaptic release machinery is a highly coordinated complex of proteins responsible for the rapid, calcium-triggered exocytosis of neurotransmitters at the synapse. The core of this machinery is the SNARE (Soluble N-ethylmaleimide-sensitive factor Attachment protein REceptor) complex, which consists of Synaptobrevin (VAMP), Syntaxin, and SNAP-25. These proteins work in tandem with calcium sensors like Synaptotagmin and regulatory proteins such as Munc18 and Munc13 to facilitate the docking, priming, and fusion of synaptic vesicles with the presynaptic membrane. This process is fundamental to neuronal communication and is the primary mechanism by which electrical signals are converted into chemical signals in the nervous system. Dysfunction of the presynaptic release machinery is implicated in a wide range of neurological and neuromuscular disorders, including epilepsy, schizophrenia, and Lambert-Eaton myasthenic syndrome. It is also the specific target of some of the most potent biological toxins known, such as Botulinum and Tetanus toxins, which cleave SNARE proteins to cause paralysis. In clinical practice, botulinum toxins are utilized therapeutically to treat conditions characterized by muscle overactivity, such as cervical dystonia, spasticity, and chronic migraine, by selectively inhibiting neurotransmitter release. Because this 'target' represents a multi-protein assembly rather than a single molecule, it is often categorized as a functional system in pharmacological contexts.
Drugs targeting this machinery typically act via the proteolytic cleavage of specific SNARE proteins (e.g., SNAP-25, Syntaxin, or VAMP/Synaptobrevin), which prevents the formation of the fusion complex and inhibits the release of neurotransmitters like acetylcholine into the synaptic cleft. Other modulators may influence the calcium-sensing components or the priming of vesicles to alter the probability of release.
6 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Presynaptic release machinery.